Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIFFANY: Tirzepatide vs Vagus Nerve Stimulation in Class I Obesity
NCT07866183Recruiting
- Sponsor
- National Medical Research Center for Therapy and Preventive Medicine
- Start
- Jun 2026
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
Randomised, open-label trial of tirzepatide in obesity (3 arms), sponsored by National Medical Research Center for Therapy and Preventive Medicine. Primary endpoints: Percentage reduction in body weight at Week 24, Percentage reduction in waist-to-height ratio at Week 24 and 2 more. Started Jun 2026; status: recruiting.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07866183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07866183.